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Introduction
The insulin-like growth factors (IGFs)' are ubiquitous peptides that diversely influence cellular proliferation and differentiation. These peptides circulate in plasma bound to specific carrier proteins (1) (2) (3) (4) (5) . The IGF-binding proteins (IGF-BPs) serve not only to transport IGFs in the circulation (5, 6) , but also to prolong their serum half-life (4, 6) , modulate tissue specificity for IGF action (4, 7, 8) , and potentiate or neutralize various biologic actions of the IGFs (9) (10) (11) (12) .
Recent studies have shown that at least three structurally distinct forms of IGF-binding proteins exist. The first is a glycoprotein with an estimated molecular mass of 53 (11, (18) (19) (20) (21) (22) . These proteins are minor carriers in blood and their binding capacity in other extravascular fluids relative to IGF-BP-3 is unknown. Several other forms of IGF-BP appear to be present in extravascular fluids (23) (24) (25) .
These have been defined by unique M, estimates, failure to react with antisera specific for one of the known IGF-BPs, or a unique set offactors that control their secretion. They have not been structurally characterized.
At present, the factors regulating IGF-BP secretion are not completely defined. Plasma concentrations of IGF-BP-3 are growth hormone dependent while plasma concentrations of IGF-BP-1 and 2 are elevated in growth hormone-deficient states (5, 26) . Tissue-specific regulation of binding protein secretion by various growth factors and steroid hormones has also been recently demonstrated in a few in vitro systems (27) . Specifically, stimulation of IGF-BP secretion by IGF-I has been demonstrated in liver explants (28), myocytes (29), and human fibroblasts (21) Decidual tissue adherent to the chorion of the placental membranes was manually stripped away and rinsed in normal saline. The decidual tissue was then enzymatically digested in buffered RPMI 1640 culture media (Gibco Laboratories, Grand Island, NY) containing 0.1% Collagenase (Worthington Biochemical Corp., Freehold, NJ), 0.1% Hyaluronidase (Sigma Chemical Co., St. Louis, MO), 0.1% trypsin inhibitor, and 0.0005% deoxyribonuclease I (Worthington Biochemical Corp.). The digestion mixture was filtered through a 150-MM mesh nytex cloth (Swiss nylon monofilament; Tetko Inc., Elmsford, NY) and the resulting cell suspension was pelleted, washed, and layered onto linear density gradients of 40% Percoll (Sigma Chemical Co.). As previously demonstrated (38) , an enriched fraction of prolactin-producing decidual cell sediments at a density of 1.017-1.044 g/ml after centrifugation at 800 g for 20 min. Viability ofcells from this band was determined by trypan blue exclusion. 1 million cells/ml were then plated in collagen-coated (Vitrogen 100; Collagen Corp., Palo Alto, CA) 24-well tissue culture clusters (Costar Data Packaging Corp., Cambridge, MA) in RPMI 1640 medium supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT), 50 ,ug/ml gentamicin (Elkins-Sinn Inc., Cherry Hill, NJ), 25 Mu/ml penicillin (Gibco Laboratories), 25 M/ml streptomycin (Gibco Laboratories), and 5 Mg/ml Amphotericin B (Sigma Chemical Co.). Cells were allowed to attach to the matrix during a 48-h incubation at 370C in a humidified atmosphere of 95% air/5% CO2.
Experimental design. Cell cultures were maintained an additional 120 h in either control medium supplemented only with antibiotics, or media additionally supplemented with one or more of the following: (a) human recombinant IGF-I (10-1,000 ng/ml; Fujisawa Pharmaceutical Co., Osaka, Japan); (b) human semi-synthetic regular insulin (10-10,000 ng/ml, Novolin; Squibb Novo, Princeton, NJ); (c) porcine relaxin (National Institutes of Health, Bethesda, MD); (d) a-IR3 (100 nM), a monoclonal antibody to the type I IGF receptor, purified by sequential precipitation in 18 and 15% sodium sulfate (39) (provided by J. J. Van Wyk, University of North Carolina, Chapel Hill, NC); or (e) 1.0 MM cycloheximide (Sigma Chemical Co.). Conditioned medium was sampled daily and exchanged completely with fresh media containing the appropriate treatments. IGF-BP concentrations in the media were assayed using an RIA specific for IGF-BP-1, the amniotic fluid binding protein, as previously described (40) . As ng/ml or insulin (A---A) HORMONE, ng/ml at concentrations ranging from 0 to 10,000 ng/ml. Each point represents the mean±SEM of triplicate samples.
that were obtained from triplicate cultures. Each point therefore is the mean of six determinants.
After 120 h of hormone exposure, cells from selected experiments were gently harvested from the collagen matrix using collagenase, and the DNA content of harvested cells was determined fluorometrically using methods described by La Barca and Paigin (42) .
Ligand blotting. A 20-,ul aliquot ofconditioned media was added to Laemmli sample buffer (43) and heated to 60°C for 10 min. Samples were then clarified by centrifugation and electrophoresed through a 12.5% SDS polyacrylamide gel. Separated proteins were transferred to nitrocellulose filters using a Janssen semi-dry electroblotter. The blots were then probed with 100,000 cpm/cm3 1251-IGF-I according to methods described by Hossenlopp (41) . '25I-IGF-I (specific activity 150-250 MCi/Mg) was prepared by a previously described method (44) and was a gift from L. Underwood (University of North Carolina, Chapel Hill, NC). Binding protein bands were then visualized by autoradiography following 3-5 d of exposure. Changes in band intensity were quantified by scanning densitometry using a Hoefer 350 scanning analysis program (Hoefer Scientific Instruments, San Francisco, CA). Band intensity changes were linear over the scanning range used in this study when pure IGF-BP-I was used as a standard.
Statistics. All experimental variables were tested in triplicate and repeated using cell cultures from at least three different pregnancies. Multivariant statistical analysis was performed using the analysis of variance with planned orthagonal contrasts. Monolayer cultures of human decidual cells were exposed for 120 h to control media (--*) or media supplemented with 100 ng/ml IGF-I (i ---.) or insulin (A---A). Samples of conditioned media were collected from successive 24-h periods and assayed for IGF-BP. Each point represents the mean±SEM of triplicate cultures. At 48 h, the P value for the inhibition of IGF-BP-I by IGF-I and insulin was < 0.01 in each instance. At 72-120 h, the P value was < 0.001 at each time.
In the experiment depicted in Fig. 1 , decidual cells were exposed to either IGF-I (100 ng/ml) or insulin (100 ng/ml) for 120 h. During the first 24-h period, IGF-BP-1 concentrations in the media of control and treated cultures were similar (data not shown). However, between 48 and 120 h, cells exposed to either growth factor released significantly less IGF-BP-1 than control cultures. The degree of inhibition of IGF-BP-1 secretion increased over time.
The inhibitory effects of IGF-I and insulin were concentration dependent (Fig. 2) . Half-maximal inhibition of IGF-BP-1 was achieved at IGF-I, and insulin concentrations of 25 ng/ml and maximal inhibition occurred at concentrations of 100 ng/ml or greater for both hormones. In this and in several other experiments insulin produced less absolute suppression ofbinding protein activity, though the pattern of IGF-BP inhibition by these two growth factors was indistinguishable.
At supraphysiologic concentrations (e.g., 1,000-10,000 ng/ml), insulin binds to the type I IGF receptor. In experiments designed to determine whether IGF-I and insulin share a common receptor pathway for inhibition of IGF-BP-I secretion, we exposed decidual cultures to a-IR3, a monoclonal (39) .
As shown in Fig. 3 , approximately one-third ofthe IGF-I effect could be inhibited by a-IR3 exposure. In contrast, the combination of insulin plus a-IR3 produced results that were not statistically different from those after treatment with insulin alone.
In contrast to IGF-I and insulin, relaxin (100 ng/ml) stimulated a marked increase in the release of IGF-BP-1 (Fig. 4) . Relaxin-treated cultures released 125±4, 369±25, 1,340±64, and 2,336±259% more IGF-BP than control cultures after 48-120 h of exposure, respectively. Relaxin-mediated effects were also dose dependent (Fig. 5) . The half-maximal and maximal effective concentrations for stimulated release of IGF-BP were 25 and 100 ng/ml, respectively. In addition, the basal and relaxin stimulated release of IGF-BP-1 was inhibited by exposure to cycloheximide (Fig. 6 ). This suggests that the increase in assayable IGF-BP-1 is primarily due to newly synthesized protein.
Comparing Figs. 4 and 1, significant variability in basal IGF-BP secretion was observed between different experiments. The etiology ofthis discrepancy is unclear though it is possible that some variability in the state ofcellular differentiation or in the purity of a cell population existed among different cell preparations. Despite this discrepancy in basal secretion rates, effects of IGF-I, insulin, and relaxin were qualitatively reproducible in all experiments.
To exclude the possibility that the changes in IGF-BP-I concentrations were the result of changes in cell number, we assayed the DNA content ofcultures after 120 h of exposure to IGF-I, insulin, or relaxin (100 ng/ml). Total DNA/million 300 -* We next determined if IGF-I or insulin could inhibit relaxin-stimulated release of IGF-BP-1. Cultures were exposed to the combination of IGF-I or insulin + relaxin. As shown in Fig. 8 , relaxin induced a 2.5-fold increase in IGF-BP-1 secretion. The addition of either IGF-I or insulin, however, completely blocked the stimulated release of binding protein by these cells.
Discussion
These experiments demonstrate that IGF-I suppresses secretion of both IGF-BP-1 and a 24,000-Mr form of IGF-BP by Figure 6 The reason for suppression of decidual IGF-BP-1 secretion by IGF-I is unclear. The IGF-BP RIA is a sensitive assay of both bound and unbound IGF-BP, and is unaffected by the presence of IGF-I in the media (40) . Therefore, the effect is not mediated by changes in IGF-I saturation, which is confirmed by gel electrophoresis data. These findings, therefore, strongly support a cell type-specific response to IGF-I exposure.
The functional significance of suppression of IGF-BP-1 secretion in decidual cell physiology has not been clearly defined. IGF-BP-1 has high affinity for IGF-I and has been shown to enhance the cellular DNA synthetic response of fibroblasts and smooth muscle cells to IGF-I (1 1). If decidual IGF-BPs similarly potentiate in utero IGF-I effects on these cell types, suppression of IGF-BP-1 secretion by IGF-I may serve as a negative feedback control mechanism for modulating cellular growth in this system. Alternatively, decidual IGF-BP has been shown to inhibit 1251I-IGF-I binding to both placental and endometrial receptors (46 The effects of relaxin on IGF-BP-I secretion have not been previously described. Extraluteal localization of relaxin to human endometrial stromal cells and decidual cells has been noted (49) (50) (51) (52) , and the uterus is a major target tissue for relaxin effects on tissue growth and myometrial contractility (53) (54) (55) (56) . The present observations suggest that relaxin may also be involved in the regulation of IGF-BP secretion by uterine tissues through autocrine or paracrine mechanisms. In The effects of relaxin, IGF-I, and insulin were significantly different from control (P < 0.001 in each instance). IGF-I and insulin inhibited the stimulation by relaxin (P < 0.001 in each instance).
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Whether such stimulation might potentiate or neutralize IGF-I action is unclear, but the observation opens up the possibility that relaxin could modulate tissue IGF responsiveness.
The potential interaction of relaxin with IGF-I or insulin receptors is -less well characterized. Although relaxin has only -25% amino acid sequence homology with the insulin-like class of growth factors (52, 53) , striking similarities of tertiary structure exist, potentially allowing for receptor cross-reactivity. Purified relaxin does not appreciably compete with binding of radiolabeled insulin to insulin receptors on IM-9 lymphocytes, leukocytes, or adipocytes (57), but the interaction of relaxin with the type I IGF receptor has not been determined. The striking stimulation seen in this study, however, in contrast to the inhibition of IGF-I and insulin, suggests that the signal allowing for this differential regulation of IGF-BP-l secretion is transduced through a distinct receptor subtype.
We have previously demonstrated that activation of adenylate cyclase stimulates the secretion of IGF-BP-l from the decidua (34). Interestingly, this intracellular signalling pathway has been implicated as a second messenger for relaxin in other systems (58) (59) (60) . Since both IGF-I and insulin block both the relaxin-and cAMP-induced stimulation of decidual IGF-BP-I synthesis, it is possible that cAMP may be mediating the relaxin signal.
In summary, a class of structurally homologous growth factors appears to play a unique role in the regulation of decidual IGF-BP secretion in vitro. The demonstration of localized in utero production of all three hormones suggests that this may represent a system of autocrine or paracrine regulatory control.
